###### Key questions

What is already known about this subject?
=========================================

-   Transcatheter aortic valve implantation (TAVI) has emerged as an effective alternative for patients who are poor candidates for surgery. While developments continue to be made to improve the devices and techniques used for TAVI, there is less solid data on the effects of non-device related procedural refinement on the outcomes and costs of TAVI.

What does this study add?
=========================

-   This study adds an evaluation of clinical outcomes and costs of transfemoral TAVI performed before and after the introduction of procedural refinements. The main refinements that were introduced included switching from general anaesthesia to conscious sedation, using percutaneous access/closure in preference to surgical cut-down and omitting periprocedural transoesophageal echocardiography. This introduction of procedural refinements facilitated a shorter stay in ICU, early discharge from hospital and resulted in lower costs.

How might this impact on clinical practice?
===========================================

-   This study provides evidence about the impact of procedural refinements to TAVI on clinical outcomes and costs. These refinements are part of ongoing quality improvement processes and have potential impact on clinical practice.

Introduction {#s1}
============

Over the last decade, transcatheter aortic valve implantation (TAVI) has emerged as an effective alternative for patients who are poor candidates for surgery.[@R1] TAVI has become the treatment of choice for symptomatic severe aortic stenosis in patients who are not suitable for surgery, and it is non-inferior to surgical aortic valve replacement in 'high-risk' operable patients.[@R6] Furthermore, there is ongoing research into the use of TAVI in intermediate and low risk patients,[@R8] making TAVI a viable alternative to surgical aortic valve replacement.

While developments continue to be made to improve the devices and techniques used for TAVI, there is less solid data on the effects of non-device related procedural refinement on the outcomes and costs of TAVI. First, in the early days of TAVI, general anaesthesia was most commonly used; however, it is also proved to be feasible to perform the procedure using conscious sedation, and this approach has gained favour in some centres.[@R11] Observational studies suggest that conscious sedation can be used without adversely affecting the overall success or safety of the TAVI procedure[@R13] and may result in lower costs.[@R18] Second, percutaneous access and closure has been associated with improvements in patients' comfort and satisfaction as well as in time to haemostasis, but needs to be balanced against periprocedural and anatomic risk factors.[@R21] Third, periprocedural transoesophageal echocardiography (TEE) has been extensively used historically, but the focus is shifting from routine use of TEE and general anaesthesia to 'as needed' use. It has been shown that its omission was associated with similar rates of paravalvular leak, similar gradients and velocities across the aortic valve and comparable 30-day outcomes but with a reduced procedure length and length of stay.[@R22] Finally, postprocedural length of stay has been shown to be a major determinant of patient outcomes and quality of life after surgical and interventional procedures. It is associated with reduced hospital-borne complications, accelerated patient recovery and mobilisation, and lower costs.[@R24]

In summary, TAVI proved to be feasible using conscious sedation without adversely affecting success and safety. Percutaneous access and closure has been associated with advantages for patients comfort as well as in time to haemostasis. Omission of routine use of TEE was associated with similar outcomes. It was for these reasons that we introduced a number of changes to our TAVI procedure in September 2015 in an attempt to make the TAVI procedure more efficient and cost-effective. Primary aim of this report was to evaluate clinical outcomes and secondary aim to evaluate costs of transfemoral TAVI performed before and after the introduction of these procedural refinements.

Methods {#s2}
=======

At our tertiary hospital, the first TAVI was performed in 2008. We introduced several procedural refinements in September 2015 ([table 1](#T1){ref-type="table"}), and a retrospective analysis was undertaken to compare outcomes and costs associated with transfemoral TAVI procedures during the 1-year period before and the 1-year period after these changes. For this purpose, all consecutive patients who underwent TAVI with an Edwards SAPIEN XT/SAPIEN 3 in the period from April 2014 to August 2015 (before the change; control group) and from September 2015 to August 2016 (after the change; procedural-refinement group) were included in the analysis. NHS Trust protocols for data collection and sharing were observed. Patients and the public were not involved in the design of the study.

###### 

Catheterisation laboratory layout and hospital stay for TAVI

                                    Control group (initial setup)                                           Procedural-refinement group
  --------------------------------- ----------------------------------------------------------------------- --------------------------------------------------------------
  Anaesthesia                       General anaesthesia                                                     Conscious sedation
  Valve implanted                   SAPIEN XT and S3                                                        SAPIEN 3
  Femoral access and closure        Surgical cut-down                                                       Predominantly percutaneous access and closure using ProGlide
  Periprocedural echocardiography   TEE and radiological guidance to facilitate precise valve positioning   Radiologically guided valve positioning; post TAVI TTE
  Scrub nurse support               1 catheter laboratory staff nurse +1 cardiothoracic staff nurse         1 catheter laboratory staff nurse
  Postprocedure care                Level 3 care on ICU                                                     Mostly cardiology ward/CCU
  Length of hospital stay           Minimum 72 hours                                                        24--72 hours

CCU, coronary care unit; ICU, intensive care unit; TAVI, transcatheter aortic valve implantation; TEE, transoesophageal echocardiogram; TTE, transthoracic echocardiography.

Cost data {#s2-1}
---------

Financial data included hospital-related direct costs associated with TAVI, comprising costs of the implantation (procedural costs). These included costs for echocardiography, prosthesis, devices and all costs as part of the implantation procedure. All other costs (ie, pacemaker implantation) were combined as non-procedural costs. Further cost data of interest were analysed (ie, costs in connection with stay on intensive care unit (ICU) or hospital ward, costs for drugs). Costs are reported in UK pounds (£) and were obtained from the department of Finance at University Hospitals Plymouth NHS Trust.

Costs were further categorised into fixed, semi-fixed and variable costs based on acute health clinical costing standards[@R28] provided by Healthcare Financial Management Association in the UK ([www.hfma.org.uk](www.hfma.org.uk)). Fixed costs are not affected by in-year changes in activity such as rent and rates. Semi-fixed costs are fixed for a given level of activity, but change in steps when activity levels exceed or fall below these given levels; nursing costs are an example. Variable costs are costs that vary with changes in activity, for example, devices (valve, closure device, etc).

Statistics {#s2-2}
----------

Primary outcomes of interest were procedure-related complications (myocardial infarction, stroke, tamponade, pacemaker (PM) implatation, etc) and death. Secondary outcome parameters were procedural costs and length of stay on ICU as well as in hospital stay.

Data were analysed descriptively; continuous variables were expressed as the mean±SD and categorical variables as number and percentage of the group. The non-parametric Mann-Whitney U test was used for testing statistical significance. A p value of \<0.05 indicated statistical significance.

Results {#s3}
=======

TAVI was performed in 70 patients during the control (pre-change) period and in 89 patients after the introduction of procedural refinements. All patients had aortic stenosis except two who had aortic regurgitation; valve disease was degenerative in all patients except three who had received a previous bio-prosthesis. Patient characteristics are summarised in [table 2](#T2){ref-type="table"}. The mean age of patients was 82.4±7.5 years in the control group and 80.9±8.3 years in the procedural-refinement group. The proportion of women was slightly higher in the control group compared with the procedural-refinement group (48.6% vs 36.0%), as was the proportion of smokers (60.0% vs 49.4%) and patients who had a previous balloon aortic valvuloplasty (28.6% vs 16.9%); however, none of these differences were statistically significant. There were no significant differences in baseline ECG or echocardiographic characteristics between the groups ([table 2](#T2){ref-type="table"}).

###### 

Patient characteristics

  -------------------------------------------------------------------------------------------------------------------------------
                                    Total\                     Control group\            Procedural-refinement group\   P value
                                    Mean±SD or n (%) (n=159)   Mean±SD or n (%) (n=70)   Mean±SD or n (%) (n=89)        
  --------------------------------- -------------------------- ------------------------- ------------------------------ ---------
  Age (years)                       81.5±8.0                   82.4±7.5                  80.9±8.3                       0.380

  Female gender                     66 (41.5)                  34 (48.6)                 32 (36.0)                      0.109

  Smoker former or current          86 (54.1)                  42 (60.0)                 44 (49.4)                      0.185

  Aortic valve pathology                                                                                                0.583

   Degenerative                     156 (98.1)                 68 (97.1)                 88 (98.9)                      

   Previous bioprosthesis           3 (1.9)                    2 (2.9)                   1 (1.1)                        

  Comorbidities/history                                                                                                 

   COPD                             23 (14.5)                  9 (12.9)                  14 (15.7)                      0.609

   Previous stroke                  10 (6.3)                   4 (5.7)                   6 (6.7)                        1.000

   Previous myocardial infarction   36 (22.6)                  17 (24.3)                 19 (21.3)                      0.660

   Previous PCI                     23 (14.5)                  8 (11.4)                  15 (16.9)                      0.334

   Previous BAV                     35 (22.0)                  20 (28.6)                 15 (16.9)                      0.077

   Previous CABG                    37 (23.3)                  16 (22.9)                 21 (23.6)                      0.913

  Logistic Euro Score (%)           13.1±9.9                   14.4±11.2                 11.8±8.4                       0.217

  **ECG and echocardiography**                                                                                          

  Rhythm                                                                                                                0.278

   Sinus rhythm                     107 (67.3)                 45 (64.3)                 62 (69.7)                      

   Atrial fibrillation              38 (23.9)                  16 (22.9)                 22 (24.7)                      

   Paced                            14 (8.8)                   9 (12.9)                  5 (5.6)                        

  LVEF                                                                                                                  0.755

   \<30%                            13 (8.2)                   5 (7.1)                   8 (9.0)                        

   30%--49%                         28 (17.6)                  11 (15.7)                 17 (19.1)                      

   \>49%                            118 (74.2)                 54 (77.1)                 64 (71.9)                      

  Pulmonary hypertension            19 (11.9)                  10 (14.3)                 9 (10.1)                       0.421

  Mitral regurgitation                                                                                                  0.612

   None or mild                     143 (89.9)                 62 (88.6)                 81 (91.0)                      

   Moderate to severe               16 (10.1)                  8 (11.4)                  8 (9.0)                        
  -------------------------------------------------------------------------------------------------------------------------------

BAV, balloon aortic valvuloplasty; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.

Clinical outcomes {#s3-1}
-----------------

Procedural characteristics, complications and outcomes are summarised in [table 3](#T3){ref-type="table"}. Femoral access and closure was generally achieved percutaneously in patients in the procedural-refinement group, whereas surgical cut-down was usually performed in the control group. Approximately half of the patients in the control group received a SAPIEN 3 valve and half received a SAPIEN XT valve. In the procedural-refinement group all except one patient received a SAPIEN 3 valve.

###### 

Procedural characteristics, complications and outcomes

  ---------------------------------------------------------------------------------------------------------------
  Procedural characteristics                Control group\   Procedural-refinement group n (%) (n=89)   P value
                                            n (%) (n=70)                                                
  ----------------------------------------- ---------------- ------------------------------------------ ---------
  Femoral approach                                                                                      \<0.001

   Surgical                                 68 (97.1)        0 (0)                                      

   Percutaneous                             2 (2.9)          89 (100)                                   

  Femoral closure                                                                                       \<0.001

   Surgical                                 68 (97.1)        3 (3.4)                                    

   Device                                   2 (2.9)          86 (96.6)                                  

  Valve type                                                                                            \<0.001

   Sapien XT                                37 (52.9)        1 (1.1)                                    

   Sapien 3                                 33 (47.1)        88 (98.9)                                  

  **Complications and outcomes**                                                                        

  Myocardial Infarction (STEMI)             0\* (0)          0 (0)                                      n.a.

  Stroke                                    2\* (2.9)        0 (0)                                      0.189

  Tamponade                                 1\* (1.4)        3 (3.4)                                    0.632

  Pacemaker implantation post-TAVI          1\* (1.4)        7 (7.9)                                    0.139

  Major access site vascular complication   2 (2.9)          4 (4.5)                                    0.695

  Conversion to open surgery                1 (1.4)          1 (1.1)                                    1.000

  Post-TAVI aortic regurgitation                                                                        0.189

   None/mild                                67\* (97.1)      89 (100)                                   

   Moderate/severe                          2\* (2.9)        0 (0)                                      

  Death within 30 days                      2 (2.9)          0 (0)                                      0.192

  Death within 1 year                       9 (12.9)         7 (7.9)                                    0.299
  ---------------------------------------------------------------------------------------------------------------

\*n=1 missing (n=69).

n.a., not applicable; STEMI, ST-elevation myocardial infarction; TAVI, transcatheter aortic valve implantation.

There were no statistically significant differences in the incidence of complications during the hospitalisation time directly after TAVI between the two groups (including major access site vascular complications, conversion to open surgery, myocardial infarction, tamponade, stroke and post-TAVI aortic regurgitation; [table 3](#T3){ref-type="table"}), although there was a non-significant trend towards a higher pacemaker implant rate in the procedural-refinement group compared with the control group (7.9% vs 1.4%, p=0.139). The rate of all-cause mortality at 1 year was 12.9% in the control group and 7.9% in the procedural-refinement group (p=0.299).

[Figure 1](#F1){ref-type="fig"} summarises the length of stay in hospital and in the ICU after TAVI. The mean time spent in the ICU after TAVI was significantly shorter in the procedural-refinement group compared with the control group, as was the mean length of stay in hospital. The stay on general ward did not differ significantly between groups.

![Length of stay in hospital and in the intensive care unit. TAVI, transcatheter aortic valve implantation.](openhrt-2019-001064f01){#F1}

Costs {#s3-2}
-----

[Figure 2](#F2){ref-type="fig"} summarises the per-TAVI costs associated with the different pathways. The total cost per TAVI procedure was significantly lower, by £3580, in the procedural-refinement group compared with the control group ([table 4](#T4){ref-type="table"}). The procedural cost directly associated to the implantation were significantly higher in the procedural-refinement group compared with the control group (by £2090); however, ICU costs were significantly lower (by £1638), as were drug costs (by £213). Hospital ward costs were also lower in the procedural-refinement group (by £261), but the difference was not statistically significant. These findings are reflected again in the procedural and non-procedural costs ([figure 2](#F2){ref-type="fig"}). Procedural costs are significantly higher in the procedural refinement group and non-procedural costs are significantly higher in the control group (p\<0.001, respectively).

###### 

Cost comparison

  --------------------------------------------------------------------------------------------------------------
                                     Control group\   Procedural-refinement group\   Mean\             P value
                                     Mean±SD in £\    Mean±SD in £\                  difference in £   
                                     (n=70)           (n=89)                                           
  ---------------------------------- ---------------- ------------------------------ ----------------- ---------
  Total                              29 923±12 168    26 343±6399                    −3580             0.001

   Fixed costs                       1324±1070        803±454                        −521              \<0.001

   Semifixed                         9975±8132        5262±2971                      −4713             \<0.001

   Variable                          18 625±6250      20 278±4431                    +1653             0.004

  Costs of special interest                                                                            

   Procedural costs (implantation)   17 308±6023      19 398±4291                    +2090             \<0.001

   Intensive care unit               1838±3001        200±574                        −1638             \<0.001

   Ward                              1603±2083        1342±1267                      −261              0.519

   Drugs                             445±313          232±144                        −213              \<0.001
  --------------------------------------------------------------------------------------------------------------

Costs were categorised into fixed, semi-fixed and variable costs based on acute health clinical costing standards[@R28] provided by Healthcare Financial Management Association in the UK ([www.hfma.org.uk](www.hfma.org.uk)). Fixed costs are not affected by in-year changes in activity such as rent and rates. Semi-fixed costs are fixed for a given level of activity but change in steps when activity levels exceed or fall below these given levels; nursing costs are an example. Variable costs are costs that vary with changes in activity,for example, devices (valve, closure device etc.). Non-parametric test used (Mann-Whitney U test).

![Cost comparison before and after the introduction of procedural refinements. Costs were categorised into fixed, semi-fixed and variable costs based on acute health clinical costing standards[@R28] provided by Healthcare Financial Management Association in the UK ([www.hfma.org.uk](www.hfma.org.uk)). Fixed costs are not affected by in-year changes in activity such as rent and rates. Semi-fixed costs are fixed for a given level of activity but change in steps when activity levels exceed or fall below these given levels; nursing costs are an example. Variable costs are costs that vary with changes in activity, for example, devices (valve, closure device, etc). non-parametric test used (Mann-Whitney U test).](openhrt-2019-001064f02){#F2}

Discussion {#s4}
==========

This analysis of transfemoral TAVI procedures performed at a single institution showed that, compared with a control group treated using the previous setup, the introduction of procedural refinements had no adverse effect on TAVI outcomes, but was associated with a reduction in the length of ICU and hospital stay and was cost saving. The main refinements that were introduced included switching from general anaesthesia to conscious sedation, using percutaneous access/closure in preference to surgical cut-down and omitting periprocedural TEE. With adequate proctor guidance, TAVI procedure using conscious sedation and 'refinement' is suited to be adopted by new centres starting TAVI procedures.

In the past, TAVI was usually performed under general anaesthesia and involved periprocedural TEE. However, as experience with TAVI has increased, some centres have moved towards a minimalist approach, whereby the procedure is performed in a catheterisation laboratory using local anaesthesia with or without conscious sedation and without periprocedural TEE. Meta-analyses of observational studies support the use of local anaesthesia/conscious sedation as an alternative to general anaesthesia in appropriate patients undergoing TAVI.[@R16] This approach reduces the invasive nature of the procedure, as well as potentially reducing the resources required and the costs.[@R18] It has also been shown that periprocedural TEE can be omitted without compromising outcomes after TAVI, and that this is associated with a reduced procedural time and shorter length of stay in hospital.[@R22] Percutaneous access and closure can be used safely in appropriate patients and can facilitate quicker ambulation and improved comfort for patients.[@R21] These procedural refinements were introduced at our centre without any adverse effects on TAVI outcomes, the incidence of complications or mortality.

Complications that can occur after TAVI include paravalvular leakage/aortic regurgitation, permanent pacemaker implantation, stroke and access-site vascular complications.[@R34] The incidence of adverse events in the current study are consistent with rates reported previously.[@R34] A trend towards a higher rate of post-TAVI pacemaker implantation was noted in the procedural-refinement group compared with the control group, although the difference did not achieve statistical significance. It is possible that this difference could relate to the valves used. At our hospital, the SAPIEN XT valve has been supplanted by the new-generation SAPIEN 3 valve over time. During the control period, patients received either a SAPIEN XT or a SAPIEN 3 valve, whereas during the procedural-refinement period all but one patient received a SAPIEN 3 valve. It was anticipated that this new-generation valve would facilitate the introduction of the procedural refinements such as the use of a conscious sedation pathway, because it uses a smaller diameter (14F/16F) femoral sheath, allows for percutaneous femoral closure and has an improved delivery system to facilitate precise positioning of the valve based on radiological guidance, as well as a new external skirt designed to minimise the risk of significant aortic regurgitation.[@R36] An increased rate of pacemaker implantation has been reported with the SAPIEN 3 valve compared with the SAPIEN XT in some (but not all) studies; the risk appears to be declining as experience with the valve increases.[@R37] There is some evidence the risk may be affected by implantation depth, oversizing and pre-existing right bundle branch block.[@R41] Nonetheless, a meta-analysis of studies comparing the SAPIEN 3 and SAPIEN XT valves found that the SAPIEN 3 was associated with a higher rate of successful implantation, fewer perioperative complications and similar rates of permanent pacemaker implantation, cerebrovascular events and early all-cause mortality.[@R43]

Pressure on healthcare resources means that in addition to optimising outcomes it is important to develop treatment strategies that are cost-effective. Most of the costs associated with the index episode of care for TAVI relate to procedural/hospital-related factors.[@R44] In particular, a prolonged stay in the ICU is associated with increased costs,[@R44] and periprocedural complications can prolong length of stay and increase costs.[@R45] The procedural changes we introduced led to a reduced need for ICU care after the procedure and a shorter overall length of stay in hospital. The mean ICU stay decreased by 52.1 hours and the mean hospital length of stay by 1.9 days in the procedural-refinement group compared with the control group. This is consistent with studies that have found that use of a local anaesthesia/conscious sedation pathway was associated with shorter procedure time and ICU and hospital stays compared with a general anaesthesia pathway,[@R16] with a meta-analysis reporting mean differences of −0.18 days for ICU length of stay and −2.09 days for hospital length of stay.[@R16] The analysis of costs in the current study showed that the procedural-refinement pathway was cost saving compared with the previous pathway. Although implantation costs were higher for patients in the procedural-refinement group, an overall reduction in costs was seen compared with the previous pathway, predominantly because of a shorter ICU stay. A mean cost saving of £3580 per TAVI procedure was achieved.

Most studies evaluating the effect of TAVI procedural refinements on costs have focused on the use of conscious sedation versus general anaesthesia pathways. These analyses have found that a local anaesthesia/conscious sedation pathway is cost saving compared with general anaesthesia.[@R14] In a study that included a subgroup of patients given SAPIEN XT or SAPIEN 3 valves via the transfemoral route, the total direct cost was approximately 25% lower in the conscious sedation group compared with general anaesthesia (p\<0.001), with significant reductions seen in each of the individual cost elements considered (anaesthesia, operating-room recovery, ICU, pharmacy and ward).[@R20] ICU and hospital lengths of stay were significantly shorter in the conscious sedation group (30 vs 61 hours, p\<0.001; and 4.9 vs 8.8 days, p=0.006, respectively).[@R20] An earlier study, involving transfemoral TAVI with the first-generation SAPIEN valve, also found that a minimalist approach using conscious sedation in a catheterisation laboratory was associated with significantly lower mean hospital costs compared with a standard approach using general anaesthesia in a hybrid operating room (US\$45 483 vs US\$55 377, p\<0.001); in this study, hospital costs included the cost of the valve but not physician fees.[@R18] Again, a shorter ICU stay (22 vs 28 hours, p\<0.001) and hospital length of stay (4 vs 6 days, p=0.01) were seen in the conscious sedation group.[@R18]

The current study has several limitations. The control group included some patients who received SAPIEN 3 valves as well as patients treated with SAPIEN XT valves; this will have blunted the effect of the higher cost of the SAPIEN 3 valve which would have been more apparent in the procedural-refinement group had there been a strict separation of valve types. However, in a routine clinical practice setting, multiple procedural refinements cannot generally be implemented all at once; there will often be overlap of certain elements over time. This also applies to the type of femoral access/closure used and the use of TEE. This could potentially have affected some outcomes in the study. In addition, the study included a relatively low number of patients. This may have limited the power to detect significant differences; clinically relevant differences may not have translated into statistical significance. Although the number of patients was relatively low, the analysis was based on an unselected consecutive series of patients undergoing transfemoral TAVI at the same centre either before or after the introduction of procedural refinements; data such as this from a real-world setting may be relevant for similar centres that perform TAVI. Finally, procedural refinements such as those described for this study are part of ongoing quality improvement processes which are never completed. As such, the analysis may need to be repeated at other points in the future.

Conclusion {#s5}
==========

In this study, the overall clinical effectiveness and safety of the procedural refinements for transfemoral TAVI seemed to be equivalent to the former approach, although these findings need to be confirmed in larger studies with longer follow-up time. However, compared with the preceding setup, introducing procedural refinements facilitated a shorter stay in ICU, earlier discharge from hospital and reduced costs.
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